Quotient Sciences Ltd
CRDMO for Small Molecule and Synthetic Peptide Therapeutics
Quotient Sciences is a CRDMO leader in small molecule and synthetic peptide therapeutics.
Subscribed
You have successfully submitted your enquiry. Someone from our company will respond ASAP
About Us
Quotient Sciences is a leading global drug development and manufacturing accelerator (CRDMO) specialising in small molecule and synthetic peptide therapeutics. Founded in 1990 and headquartered in Nottingham, UK, the company operates state-of-the-art facilities in the UK and the US, employing over 1,300 people.
They provide integrated services across the entire drug development pathway from candidate selection and formulation development to clinical pharmacology (including Phase I trials such as first-in-human studies), real-time adaptive GMP manufacturing, and commercial-scale production.
Their flagship Translational Pharmaceutics platform uniquely combines these activities, allowing rapid iteration and optimisation of drug formulations during clinical testing. This approach breaks down traditional silos between CRO (contract research) and CDMO (contract development and manufacturing) functions, shortening development timelines by over 12 months and reducing costs for clients.
Quotient Sciences partners with biotech companies and large pharmaceutical firms to accelerate the journey from molecule to cure, focusing on complex challenges like solubility enhancement, modified-release formulations, and specialised dosage forms. Their science-led, agile model emphasises speed, quality, and patient impact, making them a trusted partner in bringing innovative medicines to market faster.
Contact Details
Website
Email Address
Address
Ruddington, Nottingham,
NG11 6JS,
United Kingdom